CN110051001A - 一种用于改善记忆的膳食补充剂 - Google Patents
一种用于改善记忆的膳食补充剂 Download PDFInfo
- Publication number
- CN110051001A CN110051001A CN201910343731.9A CN201910343731A CN110051001A CN 110051001 A CN110051001 A CN 110051001A CN 201910343731 A CN201910343731 A CN 201910343731A CN 110051001 A CN110051001 A CN 110051001A
- Authority
- CN
- China
- Prior art keywords
- dietary supplements
- memory
- acid
- improving
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 40
- 230000015654 memory Effects 0.000 title claims abstract description 28
- 102000003797 Neuropeptides Human genes 0.000 claims abstract description 12
- 108090000189 Neuropeptides Proteins 0.000 claims abstract description 12
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 claims abstract description 9
- 239000011782 vitamin Substances 0.000 claims abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 9
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 235000012730 carminic acid Nutrition 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 244000248349 Citrus limon Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 18
- 210000002569 neuron Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000008309 brain mechanism Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 230000007786 learning performance Effects 0.000 abstract description 3
- 230000007787 long-term memory Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000011534 incubation Methods 0.000 description 9
- 238000011049 filling Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 102400001111 Nociceptin Human genes 0.000 description 2
- 108090000622 Nociceptin Proteins 0.000 description 2
- 102100028646 Nociceptin receptor Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 2
- 108010020615 nociceptin receptor Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- FYHRJWMENCALJY-YSQMORBQSA-N (25R)-cholest-5-ene-3beta,26-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC[C@H](CO)C)[C@@]1(C)CC2 FYHRJWMENCALJY-YSQMORBQSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- DKISDYAXCJJSLZ-UHFFFAOYSA-N 26-Hydroxy-cholesterin Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(CO)C)C1(C)CC2 DKISDYAXCJJSLZ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010049420 RE1-silencing transcription factor Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种用于改善记忆的膳食补充剂，其各成分及重量百分含量为：神经肽30‑50％、微量元素及维生素2‑5％、不饱和脂肪酸10‑20％和助剂25‑60％；其中，所述肽配制品中包含以下几种序列的肽：EVGEIE、QKQLQ、LERNAIKKVGK和TEPGLE，本发明的膳食补充剂易于吸收、无明显副作用，可以保持神经细胞的活性，使其免受衰老相关损伤；用于预防、改善或对抗与衰老过程相关的缺陷，激活与记忆力相关的大脑机制，改善长期记忆力和程序性记忆力以及学习表现、注意力，在衰老过程中保持健康的精神。
Description
技术领域
本发明属于膳食补充剂领域，具体涉及一种用于改善记忆的膳食补充剂。
背景技术
随着经济发展，人民的整体生活水平大大提高，人民的寿命普遍延长，同时加快了我国社会老龄化的发展速度。
我国早在1999年就已经步入老龄化社会，老龄人口逐年增加。2010年第六次全国人口普查结果显示，全国大于等于60岁的老年人口达1.78亿，占总人口数的13.26％。2050年，我国60岁以上老年人将达4.51亿。全球范围老龄人口的增加导致老年痴呆患者也随之增加，美国开展了2050年阿尔茨海默症患病人数的预测研究，2050年美国65岁以上老年人患阿尔茨海默病人数达到1380万，是2010年患病人数的3倍，可见患病人数增长迅速。
随着社会老龄化的发展，各种慢性躯体性疾病影响着老年人的生命健康的同时，精神卫生问题也成为老年人生命健康的一大威胁，其中，痴呆症在老年人精神疾患中最为普遍和严重。老年痴呆是继肿瘤、心脏病、脑血管疾病之后引起老年人死亡的第四大病因。它可以引起老年人发生持续时间较长的智能损害，表现为记忆、语言、思维、计算、定向力和情感障碍及人格改变，并出现社会活动能力和自身生活能力的减退。伴随病情加剧，病人变得呆滞、无欲、长时间卧床、生活无法自理，常因褥疮、骨折、肺炎、泌尿系统感染、营养不良等继发性躯体疾病或因衰竭而死亡。
老年痴呆患者的增加将导致疾病经济负担增加，美国国家脑研究基金会估计，美国每年用于痴呆的花费超过1130亿美元，直接花费超180亿美元，间接费用估计超过940亿美元。据预测，2050年我国老年痴呆的直接经济负担每年将达7453.21亿元。老年痴呆带来的沉重经济负担和社会负担，引起了科学家的关注和研究，成为全世界关注的社会、卫生、经济问题。
目前对于老年痴呆的治疗药物主要包括ACh EI、谷氨酸受体调节剂、钙拮抗剂、金属螯合剂、改善脑循环和脑代谢药物、疫苗和基因治疗药物等，其中还有其他如中医治疗药物、精神抑制剂、降胆固醇药、抗氧化剂等。
但是，观察这些药物治疗AD的作用效果，发现没有任何一种药物能够有效治疗，它们都只是在一定程度上缓解痴呆症状，延缓疾病进展。2018年初，辉瑞制药公司也宣布关于阿尔茨海默症的潜伏期、I期、II期的早期临床试验全部失败。
因此，迫切需要一种新形式的、有效的、非药物的补充剂供老年人食用。
发明内容
本发明的目的在于提供一种用于改善记忆的膳食补充剂，其易吸收、无明显副作用，可以保持神经细胞的活性，使其免受衰老相关损伤；用于预防、改善、对抗与衰老过程相关的缺陷，激活与记忆力相关的大脑机制，预防、对抗及改善认知功能下降，支持、维持和改善长期记忆力和程序性记忆力以及学习表现、注意力，在衰老过程中保持健康的精神。
为了达到上述目的，本发明提供给以下技术方案：
一种用于改善记忆的膳食补充剂，其各成分及重量百分含量为：神经肽30-50％、微量元素及维生素2-5％、不饱和脂肪酸10-20％和助剂25-60％；其中，所述神经肽中包含以下几种序列的肽：EVGEIE、QKQLQ、LERNAIKKVGK和TEPGLE，四者的重量比例为：EVGEIE：QKQLQ：LERNAIKKVGK：TEPGLE＝1-3：1-3：1-2：1-3。
进一步，所述不饱和脂肪酸为二十二碳六烯酸、亚油酸、亚麻酸、二十碳五烯酸(EPA)。
又，所述维生素选自维生素A、维生素B、维生素C、维生素D和维生素E中的一种或几种；所述的微量元素选自碘、锌、硒、铜、钼、铬、钴、铁、锰、硅、硼、钒和镍中的一种或几种。
优选地，所述助剂为防腐剂、调味剂、着色剂、添加剂、填充剂和赋形剂中的一种或几种。
进一步，所述防腐剂选自苯甲酸、苯甲酸钠、山梨酸、山梨酸钾或对羟基苯甲酸乙酯；调味剂选自柠檬酸或苹果酸；着色剂选自胭脂红或柠檬黄；添加剂选自丁基羟基茴香醚或二丁羟基甲苯；填充剂选自淀粉或琼脂；赋形剂选自卡拉胶或明胶。
本发明所述膳食补充剂的剂型为片剂、包衣片剂、胶囊、糊剂、咀嚼片或饮用溶液。
优选地，所述包衣片剂为肠包衣剂型。
线粒体应激反应强弱与衰老和记忆状态直接相关，而痛敏肽通过与痛敏肽受体结合可减弱线粒体应激反应，加速衰老及记忆减退，本发明的膳食补充剂中，添加的神经肽制品可以抑制痛敏肽及痛敏肽受体的结合，进而增强线粒体的应激反应，延缓衰老，改善记忆；添加的活性肽易吸收、功能强、无明显副作用，非常适合作为老年人的膳食补充剂。
本发明膳食补充剂中，包含了平衡量的具有神经保护活性的不饱和脂肪酸、微量元素及维生素；选择的二十二碳六烯酸(DHA)具有辅助脑细胞发育、抗衰老、改善血液循环、降血脂的作用，是人体所必需的多不饱和脂肪酸。
与现有技术相比，本发明具有如下有益效果：
本发明的膳食补充剂具有神经保护作用，其中的神经肽制品可减少神经细胞衰老，保持神经细胞活性，使其免受衰老相关损伤，预防、改善、对抗与衰老过程相关的缺陷；激活与记忆力相关的大脑机制，预防、对抗和/或改善认知功能下降。
本发明的膳食补充剂能够支持、维持和/或改善长期记忆力和程序性记忆力以及学习表现、注意力，并且用于在衰老过程中保持或支持健康的精神功能，改善老年小鼠的记忆功能，适于改善老年人记忆。
附图说明
图1为本发明实施例1中光镜下观察的神经球。
图2为本发明实施例1中不同剂量本发明膳食补充剂对27-羟基胆固醇(27HC)诱导神经细胞衰老的保护作用。
图3为本发明实施例6中两组不同训练日逃逸潜伏期比较。
图4为本发明实施例6中两组小鼠穿越第三象限和平台的次数比较。
图5为本发明实施例6中两组小鼠停留在第三象限和平台的时间比较。
具体实施方式
以下结合具体实施例对本发明作进一步说明。
购买无菌溶液，并且在层流橱中混合终溶液；在试验前对所有必需物品进行灭菌。
用于大批分析的培养基由DMEM(Dulbecco's Modified Eagle Medium)培养基与10g/L的B27和N2、0.01％庆大霉素组成，其中加入庆大霉素以防止培养基被支原体或其它有害微生物污染，每次试验都在无菌条件下的层流橱中制备新鲜的营养培养基。
实施例1一种改善记忆的膳食补充剂
本实施例的膳食补充剂的具体配方：
神经肽40％、微量元素及维生素5％、不饱和脂肪酸20％和助剂35％，其中，所述的神经肽由比例为1：1：1：1的EVGEIE、QKQLQ、LERNAIKKVGK和TEPGLE组成。
用于试验的细胞是小鼠脑皮层神经干细胞，取小鼠胚胎14-15天的胎鼠脑皮层组织，用无菌手术器械将其剪成黄豆大小，并用200目不锈钢筛网过滤后种植于培养瓶中，37℃，5％CO2培养，5-7天待原代克隆形成后，采用机械分离方法传代，经吸管吹打，200目不锈钢筛网过滤，800r/min离心10min，弃上清，加入新鲜的神经球培养基，用吸管反复小心吹打制成单细胞悬液，以1：2比例传代(图1)。
27HC能通过血脑屏障进入脑内，高浓度的27HC能够损害神经细胞，促进神经细胞衰老继而导致生物体的衰老，10μM27HC可导致约60％的神经细胞衰老。
将初始组织培养基从细胞中除去，实验组加入含有10μM27HC的新培养基，并与细胞一起培养12小时，对照组分别加入不同浓度的本实施例膳食补充剂(浓度分别为0.5mg/ml、1mg/ml、2mg/ml、4mg/ml)与含有10μM 27HC的培养基共同培养12小时，此后观察每组的衰老阳性细胞数，结果参见图2。
由图2可见，与不同浓度的本发明膳食补充剂培养12小时后，衰老阳性细胞数比例明显下降，在4mg的高剂量组中衰老阳性细胞约10％，这表明多数的神经细胞可以被挽救，所有的剂量都具有明显的神经保护作用，说明本发明的膳食补充剂可以保持神经细胞活性，保护它们免受衰老相关损伤。
实施例2一种改善记忆的膳食补充剂片剂的制备方法
本实施例的膳食补充剂包括：神经肽50％、微量元素及维生素5％、不饱和脂肪酸15％和助剂30％，所述的神经肽由比例为2：2：1：2的EVGEIE、QKQLQ、LERNAIKKVGK和TEPGLE组成。
用1.2mm筛网将上述混合物粉末50kg，筛选到不锈钢筒中，并用翻滚型混合器以6rpm的混合速度混合10分钟，用1.2nm筛网将1kg硬脂酸镁筛选到上述混合物的不锈钢筒中。随后，用翻滚型混合器以4rpm的混合速度将所有的颗粒混合5分钟得到膳食补充剂混合物。
用约6万片/小时的压片速度压片机压制得到的混合物，使用圆形、双凸面冲头，其直径为11mm。
片剂的特性为(所有性能测试方法按照中国药典进行)：
实施例3片剂包衣的制备：
对实施例2中的片剂制作包衣。
将以下成分用推进式混合器进行混合以形成薄膜包衣悬浮液：
17.5kg 醋钛纤维素(30％水性溶液)；
0.44kg 滑石粉；
0.621kg 二氧化钛；
1.059kg 柠檬酸三乙酯。
在转鼓式包衣机中用薄膜包衣悬浮液包衣片剂至终重量为420mg/膜片。包衣片可用蜂蜡或石蜡打光。以这种方式，得到具有以下参数的薄膜包衣的白色片剂(所有性能测试方法按照中国药典进行)：
平均重量： 420±15mg；
崩解： ＜30min；
脆性： ＜1％。
实施例4胶囊制剂的制备
将实施例2的粉末混合物装填到硬明胶胶囊中，用385mg的粉末混合物装填0号或1号硬明胶胶囊。从而获得具有以下参数的胶囊(所有性能测试方法按照中国药典进行)：
平均重量：460±28.8mg(1号)；
平均重量：480±28.8mg(0号)；
崩解：＜15min；
或者，相当量的颗粒可使用2号和3号硬明胶胶囊。
实施例5饮用溶液的制备
将含有神经肽30％、微量元素及维生素5％、不饱和脂肪酸10％和助剂55％，所述的神经肽由比例为3：3：1：3的EVGEIE、QKQLQ、LERNAIKKVGK和TEPGLE组成的混合物500g溶于盛有1500g水的玻璃烧瓶中，该烧瓶装有推进式混合器,形成几乎澄清的溶液，并加水稀释至5000ml，将其通过0.45μm的薄膜滤器进行过滤以进一步澄清。将该溶液装填于带有螺旋瓶盖的20ml玻璃瓶中制成引用溶液。
实施例6本发明膳食补充剂用于老年小鼠
1.实验方法
实验对象为18(±1)月龄的C57BL/6小鼠，将小鼠随机分配至实验组和对照组中，每组15只，实验组每天用本发明实施例1的膳食补充剂0.2mg灌胃1次，对照组每天用生理盐水灌胃1次，持续3个月，之后进行水迷宫实验、定位航行实验、空间探索实验。
1.1水迷宫实验
进行水迷宫实验时，应保持周边环境安静、池内水温适宜，并且于水迷宫所在之房间内的水池周围贴上特殊符号的贴纸作为空间参照的线索。
所采用的水迷宫装置为不锈钢圆形水池，其直径为116cm，高为60cm，人工分为四个象限，并于第三象限的中点、水面下0.5-1cm的位置放置一个直径10cm的圆形站台，水池在一个光亮的屋内，在池内加入白色无毒染料使水不透明。
1.2定位航行实验
前5天进行定位航行实验，每天于固定的时间随机从4个象限将小鼠放入水中，观察其游泳和找寻目标平台的情况，共1分钟，记录小鼠从入水到找到平台的时长，此为逃避潜伏期。若小鼠在进入水池后超过2分钟仍未能顺利找到圆形站台并登台，则将其引导到圆形站台休息30秒，使其熟悉隐蔽站台的位置；潜伏期记为最高分120秒，记录小鼠寻找固定平台所需时间和速度。每天训练1次，持续5天。记录每次训练的游泳速度和逃避潜伏期。以视频采集仪器记录并分析实验小鼠的逃避潜伏期和游泳路径。
1.3空间探索实验
定位航行实验进行完毕后，开始空间探索实验，撤除第三象限的圆形站台后，将所有实验小鼠由四个象限分别放入圆形水池内，观察并记录其1分钟内于水池中的全程游泳路径。以应用软件分析其在隐蔽站台所在象限(第三象限)的停留时间，以及穿过隐蔽站台位置的穿台次数等相关参数，进行相关统计学分析。
2.结果
2.1不同处理方式对老年小鼠逃逸潜伏期及游泳速度的影响
水迷宫定向航行实验显示，随着训练次数的增加，两组小鼠寻找平台的潜伏期时间均呈现明显缩短趋势，以本发明膳食补充剂灌胃组缩短较为明显(参见图3)。
此外，实验还测量了两组小鼠的游泳速度，发现两组小鼠的游泳速度没有明显差异，因此，不会影响两组的逃逸潜伏期。
训练就是让小鼠学习并且记住平台位置的过程，从结果来看，随着训练次数的增加，两组小鼠寻找平台的潜伏期都缩短，这说明两组小鼠都在学习后一定程度上记住了平台的位置。
另外，经过对比，以本发明膳食补充剂灌胃组小鼠寻找平台潜伏期时间缩短的更多，也就是本发明膳食补充剂灌胃后小鼠学习记忆能力更强，所以本发明膳食补充剂能够改善学习记忆。
2.2不同处理方式对老年小鼠穿越平台次数及停留时间的影响
在水迷宫空间探索实验中，与对照组比较，本发明膳食补充剂灌胃实验组小鼠穿越第三象限和原平台次数分别增加了100％和200％(图4)，在第三象限和原平台位置停留时间分别增加了87％和120％(图5)。
也就是说，在定速巡航试验的时候平台是放在第三象限的，而经过5天的训练后撤去了平台进行空间探索试验，这时候小鼠并不知道平台已经撤走，它习惯性的依靠空间记忆去寻找第三象限里的平台，所以穿越第三象限和原平台次数多、在第三象限和原平台位置停留时间长的就是记忆力好的小鼠，通过结果可知，正是本发明膳食补充剂灌胃组小鼠记忆力较对照组小鼠记忆力好，说明本发明膳食补充剂能够改善老年小鼠的记忆功能。
Claims (7)
1.一种用于改善记忆的膳食补充剂，其各成分及重量百分含量为：神经肽30-50％、微量元素及维生素2-5％、不饱和脂肪酸10-20％和助剂25-60％；其中，所述神经肽中包含以下几种序列的肽：EVGEIE、QKQLQ、LERNAIKKVGK和TEPGLE，四者的重量比例为：EVGEIE：QKQLQ：LERNAIKKVGK：TEPGLE＝1-3：1-3：1-2：1-3。
2.根据权利要求1所述用于改善记忆的膳食补充剂，其特征在于，所述不饱和脂肪酸为二十二碳六烯酸、亚油酸、亚麻酸或二十碳五烯酸。
3.根据权利要求1所述用于改善记忆的膳食补充剂，其特征在于，所述维生素选自维生素A、维生素B、维生素C、维生素D和维生素E中的一种或几种；所述微量元素选自碘、锌、硒、铜、钼、铬、钴、铁、锰、硅、硼、钒和镍中的一种或几种。
4.根据权利要求1所述用于改善记忆的膳食补充剂，其特征在于，所述助剂为防腐剂、调味剂、着色剂、添加剂、填充剂和赋形剂中的一种或几种。
5.根据权利要求1所述用于改善记忆的膳食补充剂，其特征在于，所述防腐剂选自苯甲酸、苯甲酸钠、山梨酸、山梨酸钾或对羟基苯甲酸乙酯；调味剂选自柠檬酸或苹果酸；着色剂选自胭脂红或柠檬黄；添加剂选自丁基羟基茴香醚或二丁羟基甲苯；填充剂选自淀粉或琼脂；赋形剂选自卡拉胶或明胶。
6.根据权利要求1所述用于改善记忆的膳食补充剂，其特征在于，所述膳食补充剂的剂型为片剂、包衣片剂、胶囊、糊剂、咀嚼片或饮用溶液。
7.根据权利要求6所述用于改善记忆的膳食补充剂，其特征在于，所述包衣片剂为肠包衣剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910343731.9A CN110051001A (zh) | 2019-04-26 | 2019-04-26 | 一种用于改善记忆的膳食补充剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910343731.9A CN110051001A (zh) | 2019-04-26 | 2019-04-26 | 一种用于改善记忆的膳食补充剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110051001A true CN110051001A (zh) | 2019-07-26 |
Family
ID=67321074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910343731.9A Pending CN110051001A (zh) | 2019-04-26 | 2019-04-26 | 一种用于改善记忆的膳食补充剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110051001A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1929853A (zh) * | 2004-01-29 | 2007-03-14 | 奥地利依比威药品有限公司 | 神经保护性膳食补充剂 |
| WO2007112453A2 (en) * | 2006-03-28 | 2007-10-04 | Neopro Labs, Llc | Methods amd compositions for treating conditions |
-
2019
- 2019-04-26 CN CN201910343731.9A patent/CN110051001A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1929853A (zh) * | 2004-01-29 | 2007-03-14 | 奥地利依比威药品有限公司 | 神经保护性膳食补充剂 |
| WO2007112453A2 (en) * | 2006-03-28 | 2007-10-04 | Neopro Labs, Llc | Methods amd compositions for treating conditions |
Non-Patent Citations (2)
| Title |
|---|
| EMIKO OKUDA–ASHITAKA，等: "Nocistatin: a novel neuropeptide encoded by the gene for the nociceptin/orphanin FQ precursor", 《PEPTIDES》 * |
| 薛庆生: "孤啡肽和其受体的研究进展", 《国外医学.麻醉学与复苏分册》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102413834B (zh) | 聚合月桂烯的组合物 | |
| CN102413833B (zh) | 乳香部分的治疗应用 | |
| CN102786414B (zh) | 一类用于治疗和/或预防神经退行性相关疾病的化合物 | |
| CN107810002A (zh) | 左乙拉西坦的延时释放药物组合物 | |
| Shukla et al. | Learning and memory enhancing activity of polyherbal formulation on streptozotocin induced memory impairment in rats via reducing mitochondria–targeted cytochrome | |
| CN111936133A (zh) | 药物组合物、用于该组合物的赋形剂以及该组合物的用途 | |
| JP5856725B2 (ja) | うつ病治療用または予防用医薬組成物 | |
| CA3192406A1 (en) | Cannabinoid composition and application thereof in preparation of drug for treating neurodegenerative diseases such as parkinson's disease and alzheimer's disease | |
| CN101904838A (zh) | 藁本内酯在制备防治老年痴呆病症组合物中的应用 | |
| CN110051001A (zh) | 一种用于改善记忆的膳食补充剂 | |
| CN115671147B (zh) | 一种海木耳萃取物及其用途 | |
| Taiwo et al. | Cardiovascular effects of Vernonia amygdalina in rats and the implications for treatment of hypertension in diabetes | |
| Parisi et al. | A female with central anticholinergic syndrome responsive to neostigmine | |
| Smith et al. | The epidemiology of the dysfunctional microbiome in animals and in humans: The propensity for the development of non-communicable disease | |
| CN112245587B (zh) | 含nad和胆碱酯酶抑制剂的药物组合物及其用途 | |
| CN104147053A (zh) | 一种库鲁木提口服液及其制备方法 | |
| CN105919991B (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
| CN106924226A (zh) | 一种治疗动脉粥样硬化的药物组合物和应用 | |
| CN105477153B (zh) | 适应原组合物及其生产方法 | |
| JP6940631B2 (ja) | 安息香酸塩で自閉症スペクトラム障害を予防または治療するための方法 | |
| CN101229149A (zh) | 一种盐酸甲氯芬酯胃漂浮缓释胶囊及制备方法 | |
| CN104000815B (zh) | 一种含有4-羟基-2-氧代-1-吡咯烷乙酰胺的药物组合物及其应用 | |
| TW201121562A (en) | Compositions of Clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
| CN106619590B (zh) | 一种治疗神经退行性疾病的药物组合物 | |
| CN116870049B (zh) | 预防或治疗神经退行性疾病的组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190726 |